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DOI 10.1016/j.ccr.2011.09.005SUMMARYTo identify therapeutic opportunities for oncolytic viral therapy, we conducted genome-wide RNAi screens to
search for host factors that modulate rhabdoviral oncolysis. Our screens uncovered the endoplasmic retic-
ulum (ER) stress response pathways as important modulators of rhabdovirus-mediated cytotoxicity. Further
investigation revealed an unconventional mechanism whereby ER stress response inhibition preconditioned
cancer cells, which sensitized them to caspase-2-dependent apoptosis induced by a subsequent rhabdo-
virus infection. Importantly, this mechanism was tumor cell specific, selectively increasing potency of the
oncolytic virus by up to 10,000-fold. In vivo studies using a small molecule inhibitor of IRE1a showed dramat-
ically improved oncolytic efficacy in resistant tumor models. Our study demonstrates proof of concept for
using functional genomics to improve biotherapeutic agents for cancer.INTRODUCTION
Despite major advances in our understanding of cancer over
the last 50 years, it remains one of the most important health
challenges worldwide. Innovative approaches are needed to
complement current therapeutic strategies, and oncolytic
viruses represent one such promising tool in the fight against
cancer (Va¨ha¨-Koskela et al., 2007). In oncolytic virus therapy
(OVT), replicating viruses selectively target tumors based on
the genetic abnormalities of their malignant cells, including
aberrant cell division, innate immune defects, and tumor-spe-
cific gene expression (Sinkovics and Horvath, 2008). In addition
to inducing direct tumor cell lysis, a productive virus infectionSignificance
Although therapeutic approaches using tumor-killing viruses (o
with response rates in Phase II trials ranging from 30% to 7
screened the human genome looking for potent opportunitie
work reveals that tumor cells can be tricked into turning on a
protein-folding machinery. These ‘‘reprogrammed’’ tumor cel
fected by an oncolytic virus. This ‘‘one-two punch’’ is cance
regresses tumors that are resistant to either therapy alone.
Cleads to recruitment of the patient’s immune system to attack
the tumor (Parato et al., 2009), and modulation of the tumor
vasculature to starve and kill cancer cells en masse (Breitbach
et al., 2007). In aggregate, the high tumor selectivity, multimodal
mechanisms for tumor destruction, and lack of genotoxicity
with OVT offer great potential for increasing efficacy while elim-
inating the side and late effects that plague current therapeutic
strategies. Over the past decade a growing number of natural
and genetically modified viruses have been shown to cure
disease in a diverse set of rodent tumor models (Sinkovics
and Horvath, 2008; Va¨ha¨-Koskela et al., 2007). Importantly,
three such virus platforms are now entering late-phase clinical
trials following impressive Phase II data (Kaufman and Bines,ncolytic viruses) are showing great promise in human trials,
0%, clearly not all patients are benefiting. In this study we
s to sensitize cancer cells to oncolytic virus therapy. Our
dormant suicide pathway by causing a mild stress to their
ls are triggered to die only when they are subsequently in-
r selective, can be induced genetically or chemically, and
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Figure 1. Genome-wide Screen Identifies ER Stress Response Blockade as a Potent Sensitizer to Rhabdovirus-Mediated Oncolysis
(A) Schematic representation of the screen.
(B) Venn diagram outlining the number of overlapping hits, and a table (+, synthetic lethal;, no interaction) and schematic diagram (hits outlined in red) illustrating
key hits within the UPR and ERAD pathways.
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communication).
Host/virus interactions at the cellular and organismal level
govern the outcome of any virus encounter, including OVT.
Thus far, most efforts to improve OVT have focused on geneti-
cally modifying the virus. However, the outcome of any host/
virus interaction is governed by contributions from both
genomes. We sought to understand the host’s contribution to
the oncolytic virus effect by using functional genomic screening
to elucidate the molecular mechanisms that control a productive
rhabdoviral infection and contribute to rhabdovirus-mediated
tumor cell killing. By understanding these mechanisms in detail,
we envisioned that we could engineer maximally effective thera-
peutic viruses, and/or design potent drug/virus combinations
that exploit unforeseen biological interfaces between oncolytic
viruses, the host and cancer.
RESULTS
Blockade of the Endoplasmic Reticulum (ER) Stress
Response Sensitizes Cancer Cells toward Viral
Oncolysis
Wild-type and engineered strains of rhabdoviruses, such as
vesicular stomatitis virus (VSV) and more recently Maraba virus,
have been shown to be potent oncolytic agents in several rodent
models of cancer (Stojdl et al., 2000b, 2003; Balachandran and
Barber, 2000; Brun et al., 2010). To search for host factors that
modulate rhabdovirus-mediated oncolysis, we performed a syn-
thetic lethal RNAi screen of the human genome across three
tumor-derived cell lines (Figure 1A). We used an arrayed library
of siRNA pools to target 18,200 genes in OVCAR-8 (ovarian
carcinoma), U373 (glioblastoma), or NCI-H226 (nonsmall cell
lung carcinoma) cells. Transfected cells were either mock in-
fected or infectedwithwild-typeMaraba virus as a representative
oncolytic rhabdovirus. Following infection we incubated the cells
for 48–72 hr, after which we scored cell viability using resazurin
vital dye. To identify primary ‘‘hits,’’ we analyzed data from two
independent screens for each cell line using themedian absolute
deviation method (Chung et al., 2008). Subtracting those genes
scoring positively in the siRNA alone screens defined 1008
synthetic lethal hits common to at least 2 out of 3 cancer lines
from the primary screen (Figure 1B, and see Table S1 available
online). Subsequent bioinformatics analysis revealed an enrich-(C) U373 cells were treated with siRNA for 72 hr prior to Maraba virus infection, an
for IRE1a is depicted. M, mock infected.
(D) EC50 shifts (black bars, left y axis) were determined for U373 cells treated with
UPR/ERAD hits from the screen. Relative mRNA expression for each gene follow
(E) Phase-contrast images of U373 cells treated first with siRNA (72 hr), followed
(F) Cell viability assays were conducted 48 hr after Maraba virus infection, in U373
[GFP]) ± siRNA targeting human ATF6a (or nontargeting [NT] control; left panel) o
panel). Western blots demonstrating gene silencing and ectopic gene expressio
(G) Representative tumor and normal cell lines were treated with siRNA targeting
48 hr later and EC50 shifts determined.
(H) Cell viability assays were performed on a panel of cancer-derived cell lines 48
IRE1a or ATF6a (72 hr).
(I) Cell viability was measured, and EC50 shifts were determined after 48 hr infec
VSV-WT, which followed 72 hr siRNA treatment.
For all experiments, *p < 0.05; data shown as ±SD.
See also Tables S1 and S2.
Cment of hits within the ER stress response pathways (Figure 1B
and Table S2), including members of two of the three known
signaling cascades that comprise the unfolded protein response
(UPR). Key hits therein included the transcription factors ATF6a
and ATF6B, the endoribonucleases/protein kinase IRE1a, and
a transcriptional coactivator common to both pathways, NFYC.
Together, the ATF6 and IRE1 pathways serve to rescue the ER
from an overload of unfolded proteins by increasing chaperone
production and ER lipid biogenesis (Todd et al., 2008). Our
screen also identified several members of the SEC61 and the
HRD ligase protein translocation complexes (e.g., Derlin-1; Fig-
ure 1B). These proteins are critical for ER-associated degrada-
tion (ERAD), which helps rescue an unfolded protein burden by
removing misfolded polypeptides from the ER and shuttling
them to the 26S proteasome (Vembar and Brodsky, 2008).
The UPR and ERAD hits were particularly interesting because
ER stress has been reported to be a defining feature of the tumor
cell state, and components of these pathways are currently
being pursued as cancer-specific targets for stand-alone treat-
ment (Hetz, 2009; Wang et al., 2009). Thus, we performed
secondary validation on ten hits within these pathways, using
siRNA with targeting sequences distinct from those employed
in the primary screens. To quantify sensitization, we infected
RNAi-treated cells with increasing doses of Maraba virus and
generated survival curves (Figure 1C). We then modeled the
curves using nonlinear regression and determined the shift in
the dose of virus required to kill 50% of the cells (EC50 shift). In
all cases in which RNAi induced significant gene knockdown
(nine of ten targets), U373 cells were significantly sensitized to
virus-mediated killing (ranging from 1.4 to 3.7 log shifts in
EC50; Figure 1D, and representative images in Figure 1E).
Although XBP1 did not emerge from our primary screen, given
its critical function in mediating IRE1a-dependent transcription
(Glimcher, 2010) we reevaluated it using RNAi duplexes distinct
from those used in the primary screen. Indeed, these analyses
demonstrated that, similar to IRE1a and our other UPR hits,
XBP1 depletion dramatically sensitized U373 cells to Maraba
virus killing (EC50 shift, 3.2 logs, Figure 1D). To rule out off-target
effects, we performed rescue experiments for ATF6a and
IRE1a, which were chosen because they are not only represen-
tative ER stress response hits from the primary screen but also
strong candidate druggable targets. Cells stably expressing
murine ATF6a (mATF6a) were completely refractory to thed viability assays were performed after 48 hr. The ‘‘EC50 shift’’ for cells silenced
Maraba virus (48 hr) following treatment with siRNA (72 hr) targeting a series of
ing siRNA knockdown (72 hr) is depicted in white (right y axis).
by Maraba virus infection (moi 5; 24 hr). Scale bar, 100 mm.
cells ectopically expressing mouse ATF6a (or control green fluorescent protein
r human XBP1(s) (or control) ± siRNA targeting human IRE1a (or control; right
n are shown.
IRE1a for 72 hr followed by Maraba virus. Cell viability assays were performed
hr after Maraba virus infection, which followed siRNA-mediated knockdown of
tion with wild-type (WT) or attenuate (MG1) Maraba virus (Brun et al., 2010) or
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Figure 2. Synthetic Lethal Interaction between ER Stress Response Blockade and Rhabdovirus Infection Requires a Preconditioning
Process
(A) U373 cells were treated with the ER stressor TM (5 mg/ml) or Maraba virus (moi 5). Total RNA was collected and RT-PCR for XBP1 splicing performed.
(B) Cells were treated as in (A). Total cell lysates were collected and immunoblot analyses conducted (DG-ATG6a, deglycosylated ATF6a, due to the inhibitory
effect of TM on glycosylation).
(C) U373 cells were untreated () or treated with TM (5 mg/ml; 24 hr) or Maraba virus (moi 5) for 6 hr prior to TM for 24 hr (MRB + TM). Total cell lysates were
collected and immunoblots performed.
(D) U373 cells were treated with putative IRE1a small molecule inhibitors (2 hr) prior to TM treatment (4 hr). Total RNAwas collected and RT-PCR performed. RNAi
targeting IRE1a (72 hr) was used as a control (right panel).
(E) U373 cells were treated with compound 2 (50 mM) or controls for 4 or 48 hr prior to Maraba virus infection. Cell viability assays were performed 48 hr later.
M, mock infected.
(F) U373 cells ectopically expressing XBP1(s) (or control) were treated with compound 2 (50 mM) for 48 hr prior to Maraba virus infection. Cell viability assays were
performed 48 hr later.
(G) U373 cells were treated with compound 2 (48 hr) followed by Maraba virus (48 hr). Cell viability assays were conducted and combination index analyses
performed.
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ER Stress Response and Viral Oncolysissynthetic lethal phenotype associated with Maraba virus infec-
tion and hATF6a knockdown (Figure 1F), whereas the sensitiza-
tion phenotype induced by IRE1a knockdown was largely
reversed in cells expressing constitutively active XBP1(s) (the
product of the endonuclease activity of IRE1a; Figure 1F). Taken
together, these experiments validate our primary screening
result that Maraba virus-mediated oncolysis is greatly enhanced
by knocking down components of the UPR and ERAD pathways.
To evaluate therapeutic index, we silenced IRE1a in a series of
primary human cell lines (GM38 skin fibroblasts, normal human
astrocytes [NHAs], and Wi38 lung fibroblasts) prior to rhabdo-
virus infection. In contrast to the pronounced sensitization
observed in U373 glioblastoma cells, IRE1a knockdown had
limited to no effect on Maraba virus-mediated killing of the
normal cell lines (Figure 1G). We next examined the scope of
the synthetic lethal phenotype in a representative subset of the
NCI 60 tumor cell panel (Brun et al., 2010). RNAi-mediated
knockdown of IRE1a or ATF6a significantly sensitized the
majority of cancer cell lines tested to Maraba virus-mediated
killing (Figure 1H). Moreover, oncolysis by the prototypic onco-
lytic rhabdovirus VSV (Stojdl et al., 2000b) and an engineered
clinical candidate strain of Maraba virus (Maraba-MG1) (Brun
et al., 2010) was similarly enhanced by UPR inhibition (Figure 1I).
Collectively, these data suggest that the enhancement of rhab-
dovirus-mediated oncolysis conferred by inhibiting components
of the ER stress response is tumor cell specific and may have
widespread utility across a diverse range of tumor types.
Synthetic Lethal Interaction between ER Stress
Response Blockade and Rhabdovirus Infection
Requires a Preconditioning Process
VSV infection has recently been shown to cause ER stress (Liu
et al., 2009), and thus, at first glance the most parsimonious
mechanism to explain our synthetic lethal phenotype is an inad-
equate host cell response to virus-induced ER stress resulting in
accelerated cell death. Indeed, Maraba virus infection caused
noticeable ER stress in cancer cells, characterized by the activa-
tion of the upstream UPR sensors IRE1a (measured by XBP1
mRNA splicing; Figure 2A), ATF6a (measured by its cleavage;
Figure 2B), and PERK (measured by EIF2a phosphorylation; Fig-
ure 2B). However, as part of co-opting the host cell’s synthetic
machinery for the generation of viral progeny, rhabdoviruses
are known to potently inhibit host gene expression by blocking
mRNA transcription (Black and Lyles, 1992), nuclear to cyto-
plasmic mRNA shuttling and protein translation (Brun et al.,
2010; Stojdl et al., 2000a, 2003). Therefore, not surprisingly,
despite having strongly activated the UPR, a Maraba virus
infection did not lead to elevated levels of the representative
downstream UPR effector proteins XBP1(s) and BIP (Figure 2B).
Moreover, the expression of BIP in response to the ER poison
tunicamycin (TM) was dramatically blunted by a preceding infec-
tion with Maraba virus, further demonstrating that this rhabdo-(H) Top panel shows that U373 cells were treatedwith compound 2 (30 mM) for eith
washout’’ period, and infected with Maraba virus. Cell viability assays were pe
illustrates that U373 cells were treated with compound 2 (30 mM) (as described
collected and RT-PCR performed for XBP1 splicing.
For all experiments, *p < 0.05; data shown as ±SD. Fa, fractional effect; CI, com
See also Figure S1.
Cvirus can actively block UPR gene expression in the face of ER
stress (Figure 2C). Taken together, these results indicate that
although a Maraba virus infection generates an ER stress that
triggers the UPR-signaling cascade, it concomitantly blocks
UPR-mediated gene expression, thereby rendering the re-
sponse functionally inert. As such, an inadequate response to
virus-induced ER stress is not responsible for the observed
synthetic lethal interaction between rhabdovirus and UPR/
ERAD knockdown because the UPR is already functionally in-
hibited upon rhabdovirus infection independently of external
manipulation.
Because siRNA knockdown of UPR/ERAD targets was per-
formed for up to 72 hr before virus was added to the cultures,
we postulated that sustained inhibition during the siRNA knock-
down periodmight be responsible for the sensitization observed.
To test this idea, we synthesized a number of salicylaldehyde-
based compounds that had been reported to inhibit IRE1a
(Mannkind-Corporation, 2008) along with several variants of
the original structure. We first measured their ability to inhibit
XBP1 splicing by IRE1a in a cell-based assay and found that
several were effective in the micromolar range (representative
subset depicted in Figure 2D). We then evaluated the most
potent of these, designated compound 2, and found that it
greatly enhanced rhabdoviral oncolysis in U373 cells when
dosed for 48 hr (compound administered 48 hr and again 24 hr
prior to virus infection, i.e., sustained inhibition), but not 4 hr
(i.e., acute inhibition; Figure 2E). Importantly, drug-mediated
sensitization significantly correlated with IRE1a inhibition (Fig-
ure S1), and ectopically expressed XBP1(s) significantly reduced
the sensitization phenotype observed (Figure 2F). These data
strongly suggest that IRE1a is indeed the functional target of
compound 2, and are in agreement with a recent report demon-
strating that this class of salicylaldehyde-based compounds
directly and selectively inhibits the endonuclease activity of
IRE1a (Volkmann et al., 2011). To determine whether the interac-
tion between Maraba virus and IRE1a inhibition was synergistic
or additive, we performed combination index experiments (Chou
et al., 1994), which demonstrated that compound 2 interacted
synergistically (CI < 1.0) with Maraba virus across a range of
doses andmultiplicity of infections (mois) (Figure 2G). In contrast
we did not observe an interaction between the negative control
compound 1 and Maraba virus at any dose across the same
range (Figure 2E; data not shown). Finally, we sought to deter-
mine if the sensitization phenotype actually required IRE1a inhi-
bition at the time of virus infection. For these experiments we
treated U373 cells with compound 2 for 48 hr before washing
the cells and adding new media (i.e., ‘‘washout’’) for another
24 hr prior to Maraba virus infection. Remarkably, the degree
of sensitization was unaltered (Figure 2H, top panel) even after
the drug was removed and IRE1a activity was restored (Fig-
ure 2H, bottom panel). In fact during the course of this experi-
ment, we noticed that compound 2 was no longer inhibitinger 4 hr, 48 hr (dosed at t =48 hr and24 hr), or 48 hr, followed by a 24 hr ‘‘drug
rformed 48 hr post-virus infection and EC50 shifts determined. Bottom panel
for top panel) prior to being treated with TM (5 mg/ml) for 4 hr. Total RNA was
bination index.
ancer Cell 20, 443–456, October 18, 2011 ª2011 Elsevier Inc. 447
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Figure 3. UPR Inhibition Leads to ER Preconditioning in Cancer Cells, which Sensitizes Them to Rhabdoviral Oncolysis
(A) U373 cells were treated with siRNA (72 hr), total cell lysates were collected, and immunoblots performed.
(B) U373 cells were treated as indicated with chemical ER stressors (bortezomib [25 nM]/Geldanamycin [120 nM]; compound 1 [30 mM], compound 2 [30 mM]) for
48 hr or treated with nontargeting or IRE1a targeting siRNA for 72 hr and then fixed and imaged for the protein aggregation marker p62. PDI is amarker for the ER,
and Hoechst stains the nucleus. White arrow points to large foci of gross protein aggregation in positive control cells. Scale bars, 3 mm.
(C) Cells were treated with siRNA (72 hr), followed by infection with Maraba virus (moi 5). Total cell lysates were collected and immunoblots performed.
(D) Cells were treated as in (C) or treated with TM (5 mg/ml) for 24 hr followed by 24 hr ‘‘washout,’’ after which cells were infected with Maraba virus (moi 5) or
treated with TM (5 mg/ml). Total cell lysates were collected at the indicated time points and immunoblots performed.
See also Figure S2.
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ER Stress Response and Viral OncolysisIRE1a activity 24 hr after it was added to the media, even without
a washout. Collectively, these data demonstrate that the sensiti-
zation mediated by ER stress blockade and the triggering of
cell death by virus infection are temporally separable events.
This observation points toward a preconditioning process that
durably alters the tumor cell’s response to a subsequent rhabdo-
virus infection.
ER Preload Rewires Cancer Cells for Caspase-2-
Dependent Apoptosis
Many cancer cells accumulate unfolded proteins as a function
of their malignant nature (Moenner et al., 2007). Therefore, we
postulated that inhibiting a component of the ER stress response
might gradually lead to an unfolded protein burden in the ER of
cancer cells, which would predispose them to ER stress-medi-
ated apoptosis in response to a subsequent rhabdovirus infec-
tion. Indeed, we found that cells treated with RNAi targeting
IRE1a for 72 hr had increased levels of both BIP and MCL1
protein (Figure 3A), which are each known to be transcriptionally448 Cancer Cell 20, 443–456, October 18, 2011 ª2011 Elsevier Inc.induced following ER stress independently of IRE1a. These data
demonstrate that sustained inhibition of IRE1a in tumor cells
leads to a sufficiently large ER protein burden as to trigger a
UPR, and this was not observed in normal cells (Figure S2A).
However, immunostaining for ubiquitin or p62 revealed no gross
protein aggregation following IRE1a knockdown or compound 2
treatment (Figure 3B; Figure S2B). We also did not detect any
evidence of an active ER stress response at this time of virus
infection because early markers of UPR activation (EIF2a
phosphorylation and ATF6a cleavage) were indistinguishable
between control and IRE1a siRNA pretreated tumor cells (Fig-
ure 3C, 0 hr). Moreover, loss of IRE1a had no effect on themagni-
tude or kinetics of UPR activation following Maraba virus infec-
tion (Figure 3C), suggesting that the capacity of the tumor cell
to respond to an unfolded protein burden was not diminished
at the time of virus infection. Collectively, these data suggest
that the protein load induced upon genetic knockdown or
chemical inhibition of IRE1a was transient, having likely been
sufficiently managed by the other arms of the UPR it evoked.
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Figure 4. ERPreconditioning HasNoBearing onRhabdovirus Infectivity, Productivity, or the Ability to Secrete or Respond to Interferons, and
Does Not Lead to ‘‘Bystander Killing’’
(A) U373 cells were treated with siRNA (72 hr) prior to Maraba infection (moi 5), and phase-contrast and fluorescent microscopy images were captured following
infection. Scale bars, 100 mm.
(B) U373 cells were treated as in (A), and single-step growth analyses conducted.
(C) Production: Ovcar-4 cells treated with siRNA targeting IRE1a (or nontargeting (NT)) RNAi for 72 hr were infected with VSV-D51 (Stojdl et al., 2003) for 18 hr, at
which time the conditioned media were collected and virus neutralized. Conditioned media (gray and white bars) or nonconditioned media (complete DMEM as
a control; black bars) were then added to Vero cells for 24 hr prior to Maraba virus infection. After 48 hr infection, viability assays were performed. Respon-
siveness: conditioned media were generated from PC3 cells infected with VSV-D51 for 18 hr. Conditioned media were then added to OVCAR-4 cells that had
been treated with siRNA targeting IRE1a or NT (72 hr) (gray and white bars), or nonconditioned media (black bars) were added to untreated OVCAR-4 cells as
a control. After 24 hr, cells were infected with Maraba virus for 48 hr and viability assays performed.
(D) Black bars (control experiments) indicate U373 cells that were treated with non (NT)- or IRE1a-targeting siRNA prior to infection with Maraba virus (moi 10).
White bars (bystander experiments) showU373 cells that were infected withMaraba virus (moi 10), and after 24 hr infection, the conditionedmedia were collected
and transferred onto U373 cells that had been previously treated with NT- or IRE1a-targeting RNAi. Cell viability was assessed after 72 hr.
For all experiments, *p < 0.05; data shown as ±SD.
Cancer Cell
ER Stress Response and Viral OncolysisAs a compliment to these studies, we induced ER preload by
treating cells with either RNAi targeting IRE1a or pulsing them
with a dose of the strong ER stress inducer TM, and evaluated
how the cells responded to a further ER insult by treating them
with a second dose of TM. In these experiments we found that
the preloaded cells were able to respond to the second ER
stressor with similar kinetics and dynamics as compared to naive
cells (Figure 3D, ATF6a blots, lanes 9–10 versus 4–5). Impor-
tantly, this further ER stress did not trigger cell death (Figure 3D,
PARP blot, lanes 9–10 and 14–15 versus 7–8 and 12–13). Taken
together, these data demonstrate that IRE1a inhibition does not
sensitize cancer cells toward rhabdovirus-mediated killing as aCresult of diminished capacity to deal with virus-induced ER
stress.
Thus, we postulated that it is a response to ER stress prior to
virus infection rather than ER stress per se that is the sensitizing
agent. We first asked whether ER preload affected any aspect of
the virus life cycle in cancer cells. We noted that UPR inhibition
had no bearing on viral protein expression following a Maraba
virus infection (Figures 3C and 3D), and further experiments
confirmed that knocking down IRE1a did not alter the infectivity
(Figure 4A) or productivity (Figure 4B) of Maraba virus in cancer
cells. These data demonstrate that transient ER stress does not
affect the life cycle of Maraba virus. It is well established thatancer Cell 20, 443–456, October 18, 2011 ª2011 Elsevier Inc. 449
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Figure 5. ER Preconditioning Rewires Cancer Cells for Caspase-2- and RAIDD-Dependent Apoptosis in Response to Rhabdovirus Infection
(A) U373 cells were treated with siRNA (72 hr), followed by infection with Maraba virus (moi 5). Total cell lysates were collected and immunoblots performed.
(B) In the top panel, PC3 cells were treated for 24 hr with siRNA as indicated and then transfected with Casp2-CARD VC, Casp2-CARD VN, and pmKATE2 (RFP
transfection control). Twenty-four hours later, cells were either left untreated or infected withMaraba virus (moi = 5). Positive control cells were heated for 1.5 hr at
44C (heat shock). Cells were assessed 8 hr after virus treatment for the percentage of cells that were Venus positive (green). Scale bars, 3 mm. Bottom panel is
a histogram (top panel) with quantified caspase-2 activation denoted as the percentage of transfected cells that showed YFP complementation. A minimum of
200 cells per well from 24 replicate wells was counted.
(C) Cells were treated with siRNA (72 hr), followed by infection with Maraba virus across a 6-log dose range. After 48 hr, cell viability was measured, and EC50
curves were plotted.
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Cancer Cell
ER Stress Response and Viral Oncolysisrhabdoviruses, including Maraba virus, are exquisitely sensitive
to the human innate immune system via type I interferon sig-
naling (Mu¨ller et al., 1994). Interferons are protective cytokines
that are processed in the ER/Golgi system before being secreted
to warn neighboring cells of an impending virus encounter.
These cytokines signal through the type I interferon receptor
(IFNR1), which is also processed in the ER/Golgi system. Pre-
vious work has shown that ER stress can inhibit proper IFNR1
processing in the ER/Golgi system, which leads to IFNR1 deple-
tion and enhanced susceptibility to a rhabdovirus infection (Liu
et al., 2009). Thus, we asked whether transient ER stress could
alter a cancer cell’s ability to secrete interferon in response to
a rhabdovirus infection, or to respond to interferon secreted by
neighboring cells. Using an interferon bioassay, we found that
silencing IRE1a in OVCAR-4 cells (which have an intact inter-
feron system) had no bearing on their ability to secrete or
respond to interferon cytokines (Figure 4C). These data demon-
strate that UPR inhibition does not induce an interferon defect in
cancer cells in our assay system. Finally, we asked whether tran-
sient ER stress could sensitize cancer cells toward death
induced by other cytokines secreted uponMaraba virus infection
(e.g., TNFa), the so-called ‘‘bystander effect.’’ We did not detect
any cytotoxicity when conditioned media from virus-infected
U373 cells were transferred to U373 cells that had been pre-
viously treated with either non- or IRE1a-targeting RNAi
(Figure 4D).
Thus, we hypothesized that a transient ER stress might rewire
the cancer cell’s signaling networks toward increased cell death
upon subsequent oncolytic virus challenge. Indeed, IRE1a
knockdown greatly enhanced the kinetics of apoptosis during
Maraba virus infection, as measured by the cleavage of PARP
and members of the caspase cascade (Figure 5A). Notably,
caspase-2 was strongly activated in tumor cells (but not normal
cells) early after virus infection only when IRE1a was knocked
down (Figure 5A; Figure S3A). Bimolecular fluorescent com-
plementation analyses of caspase-2 activation by induced prox-
imity (Bouchier-Hayes et al., 2009) confirmed that caspase-2
was strongly activated in response to combined IRE1a inhibition
and Maraba virus infection (Figure 5B; Figure S3B). Caspase-2
is an initiator caspase that has been implicated in several
stress-mediated apoptotic cascades, such as those emanating
from DNA damage (Vakifahmetoglu-Norberg and Zhivotovsky,
2010) as well as ER stress (Cheung et al., 2006). To examine
the relevance of caspase-2 activation, we knocked it down
simultaneously with IRE1a and measured apoptosis following
Maraba virus infection. In these experiments caspase-2 knock-
down almost completely rescued the synthetic lethal interaction
between IRE1a knockdown and virus infection (Figures 5C and
5D). Qualitatively similar caspase-2 rescue data were obtained
when cells were rendered null for the ERAD component OS-9
(Figure 5E). Consistent with the observation that caspase-2(D) Cells were treated with siRNA (72 hr), followed by infection with Maraba virus
(E) Cells were treated with siRNA targeting OS-9 (±caspase-2i) for 72 hr followed
(F) Cells were treated with siRNA (72 hr), followed by infection with Maraba virus
curves were plotted.
(G) Cells were treated with siRNA (72 h), followed by infection with Maraba virus
For all experiments, *p < 0.05; data shown as ±SD.
See also Figure S3.
Cwas activated early following a virus infection in cells treated
with RNAi targeting IRE1a, caspase-2 knockdown inhibited
the activation of the activator caspases 8 and 9 as well as the
downstream effector caspase 3 following a virus infection in cells
treated with IRE1a siRNA. Collectively, these data suggest that
a transient ER stress preconditions cancer cells to commit
caspase-2-dependent apoptosis in response to a subsequent
Maraba virus infection.
We next asked whether caspase-2 itself senses ER preload in
response toUPR inhibition, orwhether the link fromERpreload to
caspase-2 lies upstream. By western blotting, immunostaining,
and bimolecular fluorescence complementation (BiFC) analyses,
we have been unable to detect any changes in caspase-2 levels,
localization, activation, or phosphorylation status during the
preload period (data not shown). This suggests that whereas
caspase-2 is central to sensitization, it itself is not directly respon-
sive to ER stress during the preload period. However, when we
examined the known caspase-2-interacting proteins PIDD and
RAIDD, we found that whereas PIDD was dispensable for sensi-
tization (Figure S3C), RAIDD knockdown largely rescued IRE1a
knockdown-induced sensitization (Figure 5F). Moreover, RAIDD
protein levels markedly increased throughout an ER preload
period generated by RNAi targeting IRE1a (Figure 5G) and by
compound 2 (Figure S3D), beginning at about the time cells
become sensitized. Taken together, these data demonstrate
that ER preload-mediated rewiring for caspase-2-dependent
apoptosis upon viral infection is dependent on the adaptor
protein RAIDD. Given these findings, we asked whether other
stressors that have been shown to induce caspase-2- and
RAIDD-mediated apoptosis are similarly enhanced by ER pre-
load. Indeed, we found that both genetic and chemical inhibition
of the UPR and/or ERAD dramatically sensitized tumor cells to
killing by the DNA-damaging agent doxorubicin, a phenotype
that was dependent on both RAIDD and PIDD (Figures S3E–
S3H). These data appear to indicate that ER preload alters cell
signaling upstream of caspase-2 in such a way as to generically
sensitize to anumber of caspase-2 activation complexes initiated
from disparate triggers (proposed model depicted in Figure 6).
UPR Inhibition Potentiates Oncolytic Therapy in Primary
Patient Samples and a Preclinical Model of Cancer
To evaluate the clinical relevance of this therapeutic strategy, we
examined whether compound 2 pretreatment could sensitize
freshly derived patient tumor samples to Maraba virus-mediated
oncolysis. Cell cultures isolated from three patients with primary
glioblastoma multiforme were treated with compound 2 for 48 hr
prior to Maraba virus infection, and 48 hr later, viability assays
demonstrated that each was significantly sensitized toward
death (Figure 7A).
We next sought to evaluate the efficacy in several animal
models of cancer. To begin, we undertook maximum tolerable(moi 5). Total cell lysates were collected and immunoblots performed.
by Maraba virus for 48 hr, and western blots were performed.
across a 6-log dose range. After 48 hr, cell viability was measured, and EC50
(moi 5). Total cell lysates were collected and immunoblots performed.
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Figure 6. ER Preload Rewires Cancer Cells for Caspase-2 and
RAIDD-Dependent Viral Oncolysis
Partial UPR (or ERAD) inhibition or treatment with a chemical ER stress inducer
(e.g., TM) leads to a mild ER stress in cancer cells (ER Preload). As a result, a
corrective UPR is activated, andRAIDD protein levels are increased (Rewiring).
In response to a subsequent virus infection (or DNA-damaging agent), cas-
pase-2 is activated eccentrically due to the increased surface area with which
to seed induced proximity (Trigger), and apoptosis ensues.
Cancer Cell
ER Stress Response and Viral Oncolysisdose (MTD) and pharmacokinetic (PK) studies of compound 2 in
CD-1 nude mice. These experiments showed that a single dose
of up to 1000mg/kg of compound 2 was tolerated, had a half-life
of >6 hr, and had properties consistent with efficient bio-
distribution to the extravascular tissues (Figure S4). To validate
our combination therapy approach, we chose a chemoresistant
(Boettcher et al., 2010; Hamilton et al., 1983) orthotopic OVCAR-
4 xenograft model (Louie et al., 1985) that is also refractory to
OVT. OVCAR-4 cells stably expressing firefly luciferase were in-
jected intraperitoneally (i.p.) into CD-1 nude mice. We monitored
tumor growth using in vivo optical imaging, and initiated treat-
ment during the growth phase. To induce ER preconditioning,
we treated animals with compound 2 for 3 days prior to the first
virus injection. Consistent with our findings in cell culture, combi-
nation therapy dramatically reduced tumor burden in animal
models, an effect that was sustained for >30 days with negligible
tumor regrowth (Figures 7B and 7C). In contrast, rapid regrowth
occurred after an early period of tumor regression using either
virus or compound 2 alone.
As a complement to these experiments in human xenografts,
we sought to test this treatment regimen in an immune-compe-
tent rodent tumor model. In vitro testing determined that the
EMT6 breast cancer line, which is particularly resistant to
stand-alone rhabdovirus therapy, was significantly sensitized
to oncolytic virus killing when pretreated with compound 2 (Fig-
ure 7D). Using these cells to generate a tumor model, we con-
firmed that neither drug nor virus had an appreciable effect on
tumor growth as single agents; however, combination therapy
significantly reduced tumor burden (Figure 7E). Extending com-
pound 2 treatment to more than 12 days in combination with452 Cancer Cell 20, 443–456, October 18, 2011 ª2011 Elsevier Inc.virus treatment continued to increase efficacy (Figure 7F). Taken
together, these data demonstrate proof of concept that modu-
lating the ER stress responses can be exploited to enhance
OVT in vivo. We anticipate that the ongoing development of
more clinically relevant nanomolar compounds and/or simulta-
neous targeting of multiple components of the ER stress
response may provide even greater boosts in efficacy.
DISCUSSION
Using a genome-wide RNAi-screening approach, we have
discovered that inhibiting the ER stress response preconditions
cancer cells to undergo caspase-2-dependent apoptosis when
subsequently challenged with an oncolytic rhabdovirus. This
exploitation of the host/virus interaction increased the potency
of oncolytic Maraba virus cytotoxicity by up to 10,000-fold
throughout a diverse range of tumor-derived cell lines, without
increasing toxicity in normal cells. To validate ER preload as a
clinically relevant therapeutic strategy, we show that UPR
inhibition can sensitize primary patient glioblastoma tumors to
Maraba infection. Moreover, we demonstrate that this combina-
tion strategy can improve the effectiveness of oncolytic Maraba
virus in both an immunocompetent mouse model and an immu-
nodeficient human xenograft model of cancer. This provides an
additional mechanism by which oncolytic viruses can selectively
target tumor cells and serves to further increase the therapeutic
index of this class of experimental cancer therapy. We are
currently working to identify more potent IRE1a inhibitors and
exploring the use of multiple UPR/ERAD inhibitors to further
enhance the effectiveness of this combination strategy.
We also show that the sensitization of tumor cells to Maraba
virus is dependent on a cellular response to a transient ER
stress, but not a concurrent one. This response leads to the
predisposition toward a caspase-2-mediated apoptotic death
pathway. We are currently pursuing both the mechanism by
which ER preload is able to prime a caspase-2 response in
tumor cells, as well as the means by which rhabdoviruses and
other stressors can subsequently trigger this response to kill
cells. Currently, it has been established that caspase-2 activa-
tion can occur through both PIDD-dependent and independent
mechanisms (Tinel and Tschopp, 2004) (Manzl et al., 2009). Our
data suggest that the PIDDosome is not involved in virus-
mediated activation of caspase-2 following ER preload but is
involved in its activation by doxorubicin (Figure S3). This seems
to indicate that ER stress alters cell signaling upstream of
PIDD and that ER preload can generically sensitize to a number
of caspase-2 activation complexes initiated from disparate
triggers. Consistent with this model, we have found that RAIDD
is required for sensitization and that its protein content is
markedly elevated in response to ER preload. It may be that
RAIDD is upregulated during UPR and/or ERAD responses
and that this would help prepare the cell for the decision to
commit apoptosis should the UPR/ERAD not be sufficient to
resolve the damage. Experiments are currently ongoing to iden-
tify more of the components of this potent synthetic lethal
signaling pathway.
Our study establishes a successful strategy for the rational
design of ‘‘chemical-biological combination therapies’’ using
functional genomic screening for host/virus interactions.
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Figure 7. Inhibiting IRE1a Enhances Oncolytic Therapy in Patient Tumor Samples and Murine Cancer Models
(A) Cells isolated from three patients with glioblastomamultiformewere treatedwith compound 1 or 2 (15 mM) or DMSO control for 48 hr, followed byMaraba virus
across a 6-log dose range. Cell viability assays were performed 48 hr later and EC50 shifts determined (plotted relative to DMSO control).
(B) Luciferase-tagged OVCAR-4 cells (5e6) were delivered i.p. into CD-1 nude mice. At day 14, mice were treated twice daily with compound 2 (250 mg/kg; i.p.
delivery) or vehicle for 6 consecutive days (drug TX window is outlined by the dotted lines). Maraba-MG1 treatment (1e5 PFU; IV injections) was initiated 48–72 hr
later (virus injections depicted by arrows). Tumors were regularly evaluated using IVIS bioluminescent imaging. The graph depicts relative change in luminescent
signal, which corresponds to tumor size.
(C) Representative bioluminescent images from (B).
(D) EMT6 cells were treated with compound 1 or 2 (50 mM) or DMSO control for 48 hr prior to Maraba virus infection across a 6-log dose range. Viability assays
were conducted 48 hr later and EC50 shifts determined (plotted relative to DMSO).
(E) Luciferase-tagged EMT6 cells (1e5) were implanted into the breast fat pads of Balb/c mice. Compound 1 or 2 or PBS treatment was initiated at day 7
(250mg/kg; i.p.; twice daily for 6 days; treatment window depicted by the dotted box). Maraba-DM injections (1e7 PFU; IV) commenced on day 10 (black arrows).
Bioluminescent data are plotted (as above).
(F) Kaplan-Meier curve depicting mouse survival in an EMT6model. The experiment was done as in (E), except that compound 1 and 2 treatments were extended
for an additional 6 days.
For all experiments, *p < 0.05; data shown as ±SD.
See also Figure S4.
Cancer Cell
ER Stress Response and Viral OncolysisAlthough other chemovirus combination therapies have been re-
ported, with enhancements to oncolytic efficacy (Ottolino-Perry
et al., 2010), our study demonstrates the utility of genome-scale
systematic analyses of host/virus interactions to identify unpre-
dicted synergies. This study adds to the breadth of opportunitiesCfor combinations beyond those predicted by our current molec-
ular understanding of host/tumor/virus interactions. For example
whereas it is known that rhabdoviruses induce UPR (Liu et al.,
2009) and that UPRs are largely transcriptional, vesiculoviruses
such as VSV and Maraba virus are known to block hostancer Cell 20, 443–456, October 18, 2011 ª2011 Elsevier Inc. 453
Cancer Cell
ER Stress Response and Viral Oncolysistranscriptional responses, and we show here that UPR is effec-
tively nullified during a normal virus infection of mammalian cells.
Therefore, it would not be predicted that further inhibition of this
pathway would be a fruitful avenue for a combination therapy.
Yet, our screens identified a host pathway that robustly modu-
lates rhabdovirus cytotoxicity through an unconventional mech-
anism of action where the cellular response to an ER stress, and
not the stress itself, is the critical component of oncolytic
synergy.
Finally, it is noteworthy that rhabdoviruses are currently in
clinical development (D.F.S., unpublished data), whereas UPR
(Hetz, 2009) and ERAD (Wang et al., 2009) inhibitors are being
actively pursued for cancer treatment. Our data suggest that
these agents will act synergistically when used in combination,
and support their evaluation in the clinical setting.
EXPERIMENTAL PROCEDURES
RNAi Screening
An arrayed library of siRNA pools (Dharmacon, Thermo Fisher Scientific,
Lafayette, CO, USA) was used to target 18,200 human genes in OVCAR-8
(ovarian carcinoma), U373 (glioblastoma), or NCI-H226 (nonsmall cell lung
carcinoma) cells. Tumor cells were seeded in 384-well plates (OVCAR-8,
1250 cells/well; U373, 625 cells/well; NCI-H226, 625 cells/well). Each plate
had additional control wells with a nontargeting control siRNA (Dharmacon
nontargeting Pool #2) to measure the effect of siRNA transfection on infection,
and siRNA targeting plk-1 (Dharmacon) was used to monitor knockdown effi-
ciency. Quadruplicate plate sets were reverse transfected with siRNA (10 nM)
using RNAimax (Invitrogen, USA) and incubated for 72 hr. From these, dupli-
cate sets of plates were eithermock infected or infectedwith wild-typeMaraba
virus (moi: OVCAR-8, 0.1; U373, 0.05; NCI-H226, 0.1). Infections were incu-
bated for 48 hr (OVCAR-8) or 72 hr (U373 and NCI-H226), after which resazurin
dye (20 mg/ml) was added to each well, incubated for 6 hr, and assayed for
absorbance (573 nm) to score cell viability.
In Vitro Cytotoxicity Assays with RNAi and Determination
of ‘‘EC50 shifts’’
Cells were seeded onto 96-well plates to a confluence of50%. The following
day, siRNA transfections were performed, and 72 hr later, the cells were
infected at log 10 dilutions with wild-type Maraba virus (except for Figure 1G,
which used the indicated viruses). After 48–72 hr of infection (depending on
the cell line), Resazurin sodium salt (Sigma-Aldrich) was added to a final
concentration of 20 mg/ml. After a 6 hr incubation, the absorbance was read-
at a wavelength of 573 nm. To determine the EC50, kill curves were modeled
using nonlinear regression analysis (GraphPad Prism Software) and EC50
values determined. The EC50 shift was calculated by subtracting the EC50
of UPR targeted from nontargeted cell lines, and is represented as log 10
values.
XBP1-Splicing Assays
For qualitative analyses, total RNA was extracted from cells using a standard
RNeasy spin column kit, as described by the manufacturer (QIAGEN).
RNA was reverse transcribed to cDNA using SuperScript II RT (Invitrogen)
following the manufacturer’s guidelines. Standard PCR was performed using
the following primers: XBP1-F, 50-cct tgt agt tga gaa cca gg-30; XBP1-R,
50-ggg gct tgg tat ata tgt gg-30. The PCR products were run out on a 3%
agarose gel and visualized with UV imager. Images were scanned, and
densitometry was performed using Scion Image software. For quantitative
analyses, total RNA was extracted (as above), and real-time quantification
was performed with Taqman One-Step RT-PCR Master mix reagents
(Applied Biosystems) using the following primers and probes: forward primer
50-AAGCCAAGGGGAATGAAGT-30, reverse primer 50-CCAGAATGCCCAA
CAGGATA-30; XBP1(u) probe, 50-56-FAM-AGCACTCAGACTACGTGCACCT-
3IABkFQ-30, XBP1(s) probe 50-56-JOE-CTGAGTCCGCAGCAGGTGCAGG-
3IABkFQ-30.454 Cancer Cell 20, 443–456, October 18, 2011 ª2011 Elsevier Inc.Protein Aggregate Formation
For protein aggregation imaging, cells were cultured in 384-well optical
imaging plates (Aurora Biotechnologies, Carlsbad, CA, USA) and subjected
to either chemical or genetic ER stressor as indicated for 48–72 hr, respec-
tively. Cells were fixed with 4% formaldehyde, stained, and imaged in PBS
at room temperature. Images were collected using a confocal microscope
(FluoView 1000D; Olympus Inc.) equipped with a 603 water immersion 1.2
NA objective and processed using the Fiji distribution of ImageJ (http://fiji.
sc/wiki/index.php/Fiji). P62 was detected using rabbit polyclonal antisera
(Cell Signaling Technology; #5114) and anti-rabbit Alexa 488 (Invitrogen).
Ubiquitin was detected using rabbit polyclonal antisera (Cell Signaling Tech-
nology; #3933) and anti-rabbit Alexa 488. The ER marker PDI was stained
using themousemonoclonal antibody RL77 (Thermo, USA). Cells were stained
with Hoechst 33342 to visualize nuclei. All images were acquired at 100 ms/
pixel at 512 3 512 pixel resolution with 3 pass Kalman filter processing.
Caspase-2 BiFC
To measure caspase-2 activation by induced proximity, we employed a
caspase-2 BiFC system (Bouchier-Hayes et al., 2009). Cells were reverse
transfected in 384-well format with siRNA targeting IRE1a or a nontargeting
control siRNA. Twenty-four hours later, cells were forward transfected with
a mixture of 10 ng of Casp2 CARD VN, 10 ng Casp2 CARD VC, and 5 ng
pmKATE2 (RFP; Evrogen, Moscow) using FuGENE HD (Roche, USA). After
24 hr, cells were either mock infected or infected with Maraba virus at an
moi of 5. Alternatively, an additional plate of cells was exposed to 44C heat
shock for 90 min and returned to the incubation as a positive control for
caspase-2 activation. Following 8 hr of virus infection (or post-heat shock),
cells were fixed in 4% formaldehyde and stained with Hoechst 33342 to visu-
alize nuclei. Plates were imaged using an OPERA high-throughput confocal
microscope (PerkinElmer, USA) using a 403water immersion objective. Image
analysis and quantification were performed using Acapella software
(PerkinElmer).
Small Molecule Screening
U373 cells were plated in 6-well format to a confluence of75%. The following
day, candidate small molecules were dissolved in DMSO and added directly to
the cell culture media at a range of concentrations. After 2 hr, TM (5 mg/ml) was
added, and total RNA was collected 4 hr later. RNA extraction and RT-PCR for
XBP1 splicing were performed as described above.
In Vitro Cytotoxicity Assays with Small Molecules
Cells were seeded onto 96-well plates to a confluence of50%. The following
day, siRNA transfections were performed, or small molecule IRE1a inhibition
was initiated. For the small molecules, DMSO was used as a vehicle with a
drug concentration of 20–50 mM. Drug treatment occurred for either 4 hr
(‘‘acute’’ treatment), or was reapplied at 24 hr and left for 48 hr total (‘‘sus-
tained’’ treatment). Following knockdown or chemical inhibition, the cells
were infected at log dilutions with the indicated rhabdoviruses. After 48–
72 hr of infection (depending on the cell line), Resazurin sodium salt was added
to a final concentration of 20 mg/ml. After a 6 hr incubation, the absorbance
was read at a wavelength of 573 nm.
Ovarian Xenograft Model
Human ovarian carcinoma-derived OVCAR-4 cells, adapted for biolumines-
cent imaging, were injected into 6- to 8-week-old athymic CD-1 nude mice
(i.p. injection, 53 106 cells per mouse). Untreated animals developedmeasur-
able abdominal tumors (assessed by IVIS imaging) by 4–7 days, became
icteric by 3–4 months, and had to be euthanized shortly thereafter due to
systemic disease, as characterized by enlarged cancerous liver and spleen,
pale kidneys, and cancerous lymph nodes on the abdominal mesentery. For
efficacy experiments, compound 2 (250 mg/kg; or vehicle [10% Tween 80])
was administered twice daily (i.p. injections), beginning on day 14 and ending
on day 19. Maraba-MG1 (13 105 pfu per cell) or PBS was injected IV (tail vein)
on days 16, 17, 19, 23, 25, and 27. Animals were monitored daily for weight
loss, morbidity, hind leg paralysis, and respiratory distress. Tumor images
were captured twice weekly with a Xenogen 200 IVIS system (Caliper LS,
USA), and total luminescent flux was analyzed on computerized software
(Xenogen). All animal experiments were approved by the University of Ottawa
Cancer Cell
ER Stress Response and Viral OncolysisAnimal Research Ethics Board and carried out in accordance with guidelines
of the National Institutes of Health and the Canadian Council on Animal Care.
Glioblastoma Patient Samples
Clinical samples were used in accordance with research ethics board approval
from the Institutional Ethics Board at the Montreal Neurological Institute and
Hospital (Montreal, Canada). Written informed consent was obtained for all
patient samples in this study.
Statistical Analyses
For all statistical analyses except survival curves, one- and two-way ANOVAs
were performed, followed by a Bonferroni multiple comparison’s post hoc test
to derive p values (GraphPad Prism Software). For survival curves, Mantel-Cox
log rank analysis was used to compare plots (GraphPad Prism). For all tests,
statistical significance was defined as p < 0.05.
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